Skip to main content

Table 2 Management of patients who were or were not referred to cardiology

From: Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy

 

Cardiology referral (n = 75)

No referral (n = 39)

P value

Medications

 β blockers

55 (73%)

2 (5%)

< 0.0001

 ACE inhibitors

66 (88%)

5 (13%)

< 0.0001

 MRA

10 (13%)

1 (3%)

0.06

 Loop diuretic

21 (28%)

3 (8%)

0.01

Trastuzumab interruption

74 (99%)

35 (90%)

0.03

Trastuzumab re-started

40 (53%)

25 (64%)

0.27

Completed planned trastuzumab

26 (35%)

20 (51%)

0.09

  1. Values shown are counts (percentages). Abreviations: ACE Angiotensin converting enzyme, MRA Mineralocorticoid receptor antagonist